HIV/AIDS Topics Revised U.S. Antiretroviral Therapy Guidelines Call for Earlier Treatment and Promote Raltegravir (Isentress) to a Preferred First-line Option
- Details
- Category: HIV Treatment
- Published on Friday, 04 December 2009 13:13
- Written by Liz Highleyman
On December 1, the U.S. Department of Health and Human Services (DHHS) updated its guidelines for antiretroviral therapy (ART) for HIV positive adults and adolescents. In keeping with recent research, the revision calls for earlier treatment. ART is now recommended for people with 350-500 cells/mm3, and half the expert panel favored treatment even for those with more than 500 cells/mm3. For first-line therapy, the integrase inhibitor raltegravir (Isentress) was added to the list of "preferred" options, while lopinavir/ritonavir (Kaletra) was changed to an "alternative" due to side effects.
FDA Grants Traditional Approval for Etravirine (Intelence)
- Details
- Category: HIV Treatment
- Published on Tuesday, 01 December 2009 13:13
- Written by Tibotec
On November 24, the U.S. Food And Drug Administration (FDA) granted traditional approval of Tibotec's next-generation non-nucleoside reverse transcriptase inhibitor etravirine (Intelence), based on longer-term data from 2 pivotal trials showing that the drug was safe and effective over 48 weeks in treatment-experienced HIV patients with resistant virus.
How Much Ritonavir (Norvir) Is Needed to Boost HIV Protease Inhibitors?
- Details
- Category: HIV Treatment
- Published on Friday, 06 November 2009 13:13
- Written by Liz Highleyman
It may be possible to use certain HIV protease inhibitors (PIs) with lower boosting doses of ritonavir, according to an article published in the November 13, 2009 issue of the journal AIDS. A systemic review of prior trials showed that a 50-100 mg dose of ritonavir boosted 3 PIs -- saquinavir, fosamprenavir, and darunavir -- as much as higher doses. In the case of lopinavir/ritonavir, however, raising the ritonavir dose by a small amount enabled reduction of the lopinavir dose, potentially lowering costs.
No Significant Association between Nevirapine (Viramune) and Liver Enzyme Elevation Regardless of Pregnancy Status
- Details
- Category: HIV Treatment
- Published on Tuesday, 01 December 2009 00:00
- Written by HIVandHepatitis.com
A new study of more than 2000 women published in the November 27, 2009 issue of AIDS found no significant link between use of the NNRTI nevirapine (Viramune) and liver enzyme elevation. Nevirapine use was not associated with liver toxicity in pregnant or non-pregnant women, but pregnancy itself increased the risk of liver problems in women with HIV.
Bold Efforts to Find a Cure for HIV/AIDS and New Prevention Tools Are Urgently Needed, Says NIAID Head
- Details
- Category: Search for a Cure
- Published on Thursday, 05 November 2009 00:00
- Written by HIVandHepatitis.com
There is an urgent imperative both to scale up use of proven tools of HIV treatment and prevention, and to develop bold new interventions -- from curative therapies to vaccines and other new prevention methods --according to Drs. Anthony Fauci and Greg Folkers of the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).
Raltegravir (Isentress), Etravirine (Intelence), and Boosted Darunavir (Prezista) Is Highly Effective for Treatment-experienced Adolescents
- Details
- Category: HIV Treatment
- Published on Tuesday, 17 November 2009 00:00
- Written by Liz Highleyman
An antiretroviral therapy (ART) regimen containing 3 recently approved anti-HIV drugs -- the integrase inhibitor raltegravir (Isentress), the next generation non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine (Intelence), and the ritonavir-boosted protease inhibitor darunavir (Prezista) -- was well tolerated and produced good viral suppression and CD4 cell gains in heavily treatment-experienced adolescents, according to a study published in the November 13, 2009 issue of AIDS.
Three-quarters of HIV Positive Prisoners Decrease Adherence to Antiretroviral Therapy after Release
- Details
- Category: HIV Treatment
- Published on Friday, 30 October 2009 15:34
- Written by Liz Highleyman
A large proportion of HIV positive former prisoners take their antiretroviral therapy (ART) irregularly after they are released from incarceration, thereby raising the risk of treatment failure and disease progression, according to a study in the September 22, 2009 issue of the open-access online journal PLoS One.
More Articles...
- Small Molecule Compound 5HN Flushes Out Latent HIV in Reservoir CD4 T-cells
- Meta-Analysis of Truvada vs Epzicom Backbones Used with Boosted Protease Inhibitors for First-line Antiretroviral Therapy
- ICAAC 2009: Raltegravir (Isentress) plus Atazanavir (Reyataz) Maintenance Therapy Appears Safe and Effective in Small Study
- ICAAC 2009: Nevirapine (Viramune) and Boosted Atazanavir (Reyataz) Produce Comparable Early Virological and Immunological Response
- ICAAC 2009: Tobacco and Marijuana May Significantly Lower Atazanavir (Reyataz) Blood Levels
Web Design and Development by